$PLTR

Jobs Numbers Set for Release Next Week

The article lists upcoming U.S. and Canada economic releases and scheduled earnings for the week. Key data include U.S. manufacturing and services PMIs, job openings, ADP and the employment report, and initial jobless claims. It also cites quarterly EPS figures for companies such as PLTR, VRTX, MAR, AMD, CAT, LLY, NVO, and COP, among others.

Original reporting
Published Aug 3, 2026, 5:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 6:42 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jobs Numbers Set for Release Next Week — source image
Decision brief

The 30-second read

$PLTRNeutralLow
01

Why it matters

It can help traders plan event risk around jobs-related macro prints and multiple earnings dates, but it does not disclose any new company results, guidance, or policy decisions.

02

Market read

Primary value is event timing for macro and earnings volatility, not new fundamental information.

03

What to watch

Actual market impact will depend on the surprise versus consensus at release time, which this article does not provide.

Relevance 4/10Novelty 2/10Timing: next-week earnings and US/Canada labor and jobs-related releases

Background

The piece is a next-week economic and earnings lookahead, listing scheduled US and Canada data releases and featured earnings names.

Company-level read

Ticker impact

$PLTRNeutralLow confidence
Context

The calendar lists Palantir Q2 EPS of 28 cents versus 13 cents prior-year, but provides no new results or guidance.

Expected impact

Limited immediate impact from this article alone; volatility risk exists only when the actual earnings print arrives.

Evidence & confidence

The text is a next-week preview with no new company-specific event beyond the scheduled earnings reference.

$VRTXNeutralLow confidence
Context

Vertex Q2 EPS is listed as 34 cents versus 32 cents prior-year, presented as a featured earnings item.

Expected impact

No actionable price impact from the preview itself.

Evidence & confidence

The article does not report a new print, guidance change, or management update.

$MARNeutralLow confidence
Context

Marriott Q2 EPS is listed as $3.06 versus $2.65 prior-year in the featured earnings section.

Expected impact

Preview-only, so expected impact is minimal until the actual report.

Evidence & confidence

No new data beyond the calendar-style listing.

$AMDNeutralLow confidence
Context

Advanced Micro Devices is listed for Q3 EPS of $1.35 versus 27 cents prior-year, as part of the Tuesday featured earnings.

Expected impact

Potential volatility around the actual earnings date, but not attributable to this article.

Evidence & confidence

No earnings results, guidance, or management commentary are provided.

$CATNeutralLow confidence
Context

Caterpillar Q2 EPS is listed as $6.25 versus $4.72 prior-year in the featured earnings lineup.

Expected impact

No immediate trading signal from the calendar entry alone.

Evidence & confidence

The article does not report a new print or corporate action.

$MRKNeutralLow confidence
Context

Merck Q2 EPS is listed as a loss of 26 cents versus a gain of $2.13 prior-year, as a featured earnings item.

Expected impact

Trading impact depends on the actual earnings release, not on this preview.

Evidence & confidence

No new results, guidance, or regulatory updates are disclosed.

$LLYNeutralLow confidence
Context

Eli Lilly is listed for Q2 EPS of $6.71 versus $6.31 prior-year in the Wednesday featured earnings.

Expected impact

No actionable impact until the earnings report is released.

Evidence & confidence

The article provides no fresh company event or datapoint beyond the calendar listing.

$NVONeutralLow confidence
Context

Novo Nordisk is listed for Q2 EPS of 81 cents versus 97 cents prior-year in the Wednesday featured earnings.

Expected impact

Limited impact from the preview itself.

Evidence & confidence

No new guidance, trial update, or earnings result is reported.

Market effects

Broad earnings calendar across software, semis, industrials, and healthcare, but without new sector-specific catalysts.

US and Canada macro releases (jobs, claims, GDP, PMI/services) can drive cross-asset risk sentiment.

Limited direct global linkage beyond standard macro and earnings scheduling.

Counterpoint

Because this is only a calendar preview, traders may overreact to the listed prior-year comparisons that are not forecasts or new disclosures.

Key entities

  • U.S. employment report (July)

    Scheduled for Friday, with the article framing it as the key jobs-related event.

  • Initial jobless claims (Aug 1)

    Scheduled for Thursday, a near-term labor-market risk catalyst.

  • Featured earnings (multiple tickers)

    A list of companies expected to report across Monday to Friday.

Related articles

$SNDKLow

Sandisk Just Announced a $14 Billion Stock Buyback Authorization: Warren Buffett Has a Warning Investors Shouldn't Ignore

Sandisk (SNDK) announced a $14B stock buyback, adding to its $15.5B authorization, over 7% of its market cap. The move follows strong performance in 2026, driven by AI-related demand. Warren Buffett warns buybacks should only occur at prices below intrinsic value. Sandisk's stock is up 535% this year, with net income rising from -$1.6B to $11.4B. Management expects steady growth but faces uncertainty from supply increases and market cyclicality.

$NVOMed

Novo's Wegovy Pill Enters China Behind Lilly

Novo Nordisk (NYSE:NVO) submitted its oral Wegovy pill for regulatory review in China, trading at $45.88. Eli Lilly (NYSE:LLY) had previously submitted its rival pill. China's market for obesity treatments is expected to grow significantly. Novo has not disclosed approval or launch timelines. The stock trades 58.04% below its GF Value.

$PLTRHighAI 8/10

Palantir’s Pentagon AI surge comes with a question investors can’t ignore

Palantir's Maven Smart System, an AI-enabled military intelligence tool, is approaching a $1 billion annual revenue run rate, according to William Blair. The Pentagon awarded Palantir a $795 million contract for Maven, with work through 2029. Palantir's Q2 revenue surged 93% to $1.935 billion, with U.S. government revenue up 90% to $809 million. The company secured 220 contracts worth at least $1 billion in the quarter.

$MRNAHighAI 9/10

Moderna (MRNA) & Merck (MRK): What’s Happening With These Two Stocks?

Moderna (MRNA) and Merck (MRK) announced positive Phase 3 trial results for their personalized mRNA cancer vaccine combined with Keytruda, meeting primary goals. Moderna's shares surged 177%, adding $44 billion to its market value, while Merck's shares rose 12%. The trial showed extended time without melanoma recurrence and reduced risk of cancer spread. Moderna CEO called it a validation of a new class of medicine, with analysts expecting regulatory approval soon.

$NVDAMedAI 8/10

NVIDIA (NVDA), Palantir Technologies (PLTR), and the AI Achilles’ Heel: Steve Eisman’s Concentration Warning Explained

Steve Eisman warned on CNBC that OpenAI and Anthropic contribute significantly to the revenue of major tech companies, posing a concentration risk. NVIDIA (NVDA) and Palantir (PLTR) are exposed to this risk differently. NVIDIA reported strong cash flow, while Palantir saw revenue growth and raised guidance. Michael Burry highlighted NVIDIA's reliance on a few hyperscale customers and potential financing risks. Both companies face unique challenges and opportunities related to AI.

$MRNAHighAI 9/10

Moderna (MRNA), Merck (MRK) Cancer Vaccine Wins in Late-Stage Trial

Moderna (MRNA) and Merck (MRK) announced their personalized melanoma vaccine, intismeran, combined with Keytruda, met Phase 3 trial goals, reducing cancer recurrence risk. Both companies' shares rose on the news. Full data will be presented at an upcoming medical meeting. Additional trials are ongoing for other cancers.